Resources
57 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 6/9/2021 (updated 4/10/2024)
Background: Racial/ethnic disparities in the use of opioids to treat pain disorders have been previously reported in the emergency department (ED). Further research is needed to better evaluate the impact race/ethnicity may have on the use of opioids in adolescents for the management of pain disorders in the ED.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 4/28/2021 (updated 4/10/2024)
Many people use opioids and are at risk of overdose. Naloxone is an opioid antagonist used to counter the effects of opioid overdose. There is an increased availability of naloxone in New York City; however, many who use opioids decline no-cost naloxone even when offered. Others may have the medication but opt not to carry it and report that they would be reluctant to administer it if they were to witness an overdose.
Posted 3/5/2021 (updated 4/5/2024)
The United States is facing a crisis of opioid-related overdose. At this time, more people die of overdose every year than died of AIDS at the peak of the HIV epidemic. Communities seek effective responses to prevent opioid death.
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 3/2/2021 (updated 4/4/2024)
In light of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategies are needed to address the epidemic and to efficiently engage and retain individuals in care for opioid use disorder (OUD). Moreover, there is an increasing need for novel approaches to using health data to identify gaps in the cascade of care for persons with OUD.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.